ASPIrin to Reduce Events in Dialysis (ASPIRED)
Heart disease accounts for nearly 60% of all deaths in people with kidney failure, largely due to poor health and common side-effects related to dialysis. Aspirin has been shown to reduce cardiovascular (CV) complications, but it is also associated with a higher risk of bleeding. In the general population, the protection against CV disease greatly outweighs the risks of bleeding. However, the risks and benefits of Aspirin use within the dialysis population are less known, due to a lack of large scale studies in dialysis patients for this low cost medication. Hence, there is an urgent need to fill this evidence gap addressing whether Aspirin is effective for CV disease prevention in End Stage Kidney Disease.
Aims and Objectives:
Using a pragmatic double-blind randomised placebo-controlled design, the ASPIRED Trial will determine the safety and efficacy of low dose aspirin for the prevention of cardiovascular events in people with end stage kidney disease receiving dialysis.
The ASPIRED trial is currently the largest randomised controlled trial of Aspirin in dialysis patients, with more than 500 participants enrolled in China. Further expansion across additional sites and Asia Pacific Countries is in progress.